Osteoporosis risk screening for women in a community pharmacy

Journal of the American Pharmacists Association

Volumn 47, Issue 4, 2007, Pages 521-526

  Liu, Yifei ^a   Nevins, Justin C ^a   Carruthers, Kara M ^b   Doucette, William R ^a   McDonough, Randal P ^c   Pan, Xiaoyun ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Main at Locust Pharmacy Clinic and Medical Supply   (United States)

^c Towncrest Pharmacy   (United States)

Author keywords

Bone mineral density screening; Business models; Community and ambulatory pharmacy; Cost analysis; Osteoporosis; Pharmacy services

Indexed keywords

AGED; ARTICLE; BONE DENSITY; COST; ECONOMICS; FEMALE; HUMAN; MIDDLE AGED; OSTEOPOROSIS; PHARMACY; RISK FACTOR;

AGED; BONE DENSITY; COMMUNITY PHARMACY SERVICES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS;

EID: 34447569408     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2007.05107     Document Type: Article

References (25)

1. National Osteoporosis Foundation. Fast facts. Accessed at www.nof.org/osteoporosis/diseasefacts.htm, July 12, 2004.
2. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. Accessed at http://consensus.nih.gov/2000/2000Osteoporosis111html.htm, November 8, 2005.
3. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-41.
4. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129.
5. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001;12:519-28.
6. Johnell O, Kannus P, Obrant KJ, et al. Management of the patient after an osteoporotic fracture: guidelines for orthopedic surgeons: consensus conference on Treatment of Osteoporosis for Orthopedic Surgeons, Nordic Orthopedic Federation, Tampere, Finland 2000. Acta Orthop Scand. 2001;72:325-30.
7. MacLaughlin EJ, MacLaughlin AA, Snella KA, et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy. 2005;25:379-86.
8. Kleerekoper M, Nelson DA. Peripheral bone densitometry: an old friend revisited. Trans Am Clin Climatol Assoc. 1998;109:62-70.
9. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet. 1996;348:511-4.
10. Greenspan SL, Bouxsein ML, Melton ME, et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res. 1997;12:1303-13.
11. Thompson PW, Taylor J, Oliver R, Fisher A. Quantitative ultrasound (QUS) of the heel predicts wrist and osteoporosisrelated fractures in women age 45-75 years. J Clin Densitom. 1998;1:219-25.
12. Food and Drug Administration. Hologic Sahara Clinical Bone Sonometer. Food and Drug Administration report no. P970017. Rockville, Md.: Food and Drug Administration, Department of Health and Human Services; 1998.
13. Lopez-Rodriguez F, Mezquita-Raya P, de Dios Luna J, et al. Performance of quantitative ultrasound in the discrimination of prevalent osteoporotic fractures in a bone metabolic unit. Bone. 2003;32:571-8.
14. Farina RD, Corbett AH, Edwards MD, et al. Osteoporosis screening: is screening effective? Can it be done economically? Will people pay for it? US Pharm. 1999;24:(9)38-43.
15. Rosenthal WM. Implementing bone mineral density testing in the community pharmacy. J Am Pharm Assoc. 2000;40:737-45.
16. Lata PF, Brinkley NC, Elliott ME. Acceptability of pharmacybased bone density measurement by women and primary healthcare providers. Menopause. 2002;9:449-55.
17. Elliott ME, Meek PD, Kanous NL, et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc. 2002;42:101-10.
18. Elliott ME, Meek PD, Kanous NL, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother. 2002;36:571-7.
19. Cerulli J, Zeolla M. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc. 2004;44:161-7.
20. Goode J, Swiger K, Bluml BM. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: Osteoporosis. J Am Pharm Assoc. 2004;44:152-60.
21. Summers KM, Brock TP. Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother. 2005;39:243-8.
22. National Institutes of Health. Optimal calcium intake. Accessed at http://consensus.nih.gov/1994/1994OptimalCalcium097html. htm, January 15, 2000.
23. Kent K, McDonough RP, Dinges B, Doucette WR. Retrospective financial analysis of a wellness center from an independent community pharmacy perspective. J Am Pharm Assoc. 2006;46:447-52.
24. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass. Accessed at www.nof.org/advocacy/prevalence, September 12, 2005.
25. National Osteoporosis Foundation. Osteoporosis: clinical updates: clinical uses of ultrasound. NOF online continuing medical education. Accessed at www.nof.org/cmeexam/Issue1QUS/clinical-usesof-ultrasound.htm, July 12, 2004.